AR036213A1 - Derivados de 6-fenil-pirrolo[2,3-d]pirimidina, un proceso para su preparacion, composicion farmaceutica y el uso de dichos derivados para la preparacion de composiciones farmaceuticas - Google Patents
Derivados de 6-fenil-pirrolo[2,3-d]pirimidina, un proceso para su preparacion, composicion farmaceutica y el uso de dichos derivados para la preparacion de composiciones farmaceuticasInfo
- Publication number
- AR036213A1 AR036213A1 ARP020102968A ARP020102968A AR036213A1 AR 036213 A1 AR036213 A1 AR 036213A1 AR P020102968 A ARP020102968 A AR P020102968A AR P020102968 A ARP020102968 A AR P020102968A AR 036213 A1 AR036213 A1 AR 036213A1
- Authority
- AR
- Argentina
- Prior art keywords
- derivatives
- preparation
- heterocyclic radical
- alkylene
- pharmaceutical compositions
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title 1
- 125000002947 alkylene group Chemical group 0.000 abstract 4
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- PAWABSCCOFXOCW-UHFFFAOYSA-N 6-phenyl-7h-pyrrolo[2,3-d]pyrimidine Chemical compound N1C2=NC=NC=C2C=C1C1=CC=CC=C1 PAWABSCCOFXOCW-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 125000001841 imino group Chemical group [H]N=* 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 239000011593 sulfur Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Un compuesto derivado de 6-fenil-pirrolo [2,3-d]pirimidina de la fórmula (1), en donde: R1 y R2 son cada uno independientemente del otro, hidrógeno, alquilo o cicloalquilo insustituido o sustituido, un radical heterocíclico enlazado mediante un átomo de carbono del anillo, o un radical de la fórmula R4-Y-(C=Z)-, en donde R4 es amino insustituido, mono- o disustituido, o un radical heterocíclico; Y no está presente es alquilo inferior, y Z es oxígeno, azufre o imino, con la condición de que R1 y R2 no sean ambos hidrógeno; o R1 y R2, junto con el átomo de nitrógeno con el que están unidos, forman un radical heterocíclico; R3 es un radical heterocíclico o un radical aromático insustituido o sustituido; G es alquileno C1-7, -C(=O)-, ó alquileno C1-6-C(=O)-, en donde el grupo carbonilo está unido a la fracción NR1R2; Q es -NH-, u -O-, con la condición de que Q es -O- si G es -C(=O)- ó alquileno C1-6-C(=O)-; y X no está presente no es alquileno C1-7, con la condición de que un radical heterocíclico R3 esté enlazado mediante un átomo de carbono del anillo si X no está presente; o una sal del mismo, a procesos para su preparación, a composiciones farmacéuticas que comprenden estos derivados, y al uso de estos derivados - solos o en combinación con uno o más compuestos farmacéuticamente activos diferentes - para la preparación de composiciones farmacéuticas para el tratamiento en especial de una enfermedad proliferativa, tal como un tumor.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0119249.1A GB0119249D0 (en) | 2001-08-07 | 2001-08-07 | Organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR036213A1 true AR036213A1 (es) | 2004-08-18 |
Family
ID=9919959
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020102968A AR036213A1 (es) | 2001-08-07 | 2002-08-05 | Derivados de 6-fenil-pirrolo[2,3-d]pirimidina, un proceso para su preparacion, composicion farmaceutica y el uso de dichos derivados para la preparacion de composiciones farmaceuticas |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US7244729B2 (es) |
| EP (1) | EP1416935B8 (es) |
| JP (1) | JP4147184B2 (es) |
| KR (1) | KR100597505B1 (es) |
| CN (2) | CN101560214B (es) |
| AR (1) | AR036213A1 (es) |
| AT (1) | ATE388713T1 (es) |
| AU (1) | AU2002324029B2 (es) |
| BR (1) | BR0211801A (es) |
| CA (1) | CA2453881C (es) |
| CY (1) | CY1108129T1 (es) |
| DE (1) | DE60225563T2 (es) |
| DK (1) | DK1416935T3 (es) |
| EC (1) | ECSP034444A (es) |
| ES (1) | ES2302830T3 (es) |
| GB (1) | GB0119249D0 (es) |
| HU (1) | HUP0401083A3 (es) |
| IL (2) | IL159832A0 (es) |
| MX (1) | MXPA04001191A (es) |
| MY (1) | MY140398A (es) |
| NO (1) | NO328791B1 (es) |
| NZ (1) | NZ530824A (es) |
| PE (1) | PE20030349A1 (es) |
| PL (1) | PL365783A1 (es) |
| PT (1) | PT1416935E (es) |
| RU (1) | RU2318826C2 (es) |
| SG (1) | SG156521A1 (es) |
| SI (1) | SI1416935T1 (es) |
| TW (1) | TWI324159B (es) |
| WO (1) | WO2003013541A1 (es) |
| ZA (1) | ZA200400271B (es) |
Families Citing this family (134)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE423120T1 (de) * | 2000-06-26 | 2009-03-15 | Pfizer Prod Inc | Pyrroloä2,3-düpyrimidin verbindungen als immunosuppressive wirkstoffe |
| AU2002340139A1 (en) * | 2001-10-09 | 2003-04-22 | The University Of Cincinnati | Inhibitors of the egf receptor for the treatment of thyroid cancer |
| PT1505959E (pt) | 2002-05-16 | 2009-02-05 | Novartis Ag | Utilização de agentes de ligação do receptor edg em cancro |
| NZ592039A (en) | 2003-08-27 | 2013-03-28 | Ophthotech Corp | Combination therapy for the treatment of ocular neovascular disorders |
| EP1689407A1 (en) * | 2003-11-25 | 2006-08-16 | Pfizer Products Inc. | Method of treatment of atherosclerosis |
| PE20051092A1 (es) * | 2004-01-29 | 2006-01-20 | Novartis Ag | Derivados de pirrolo-pirimidina utiles para el tratamiento de enfermedades proliferativas |
| GB0403606D0 (en) | 2004-02-18 | 2004-03-24 | Novartis Ag | Organic compounds |
| JPWO2005095419A1 (ja) * | 2004-04-01 | 2008-02-21 | 武田薬品工業株式会社 | チアゾロピリミジン誘導体 |
| DK2253614T3 (da) | 2004-04-07 | 2013-01-07 | Novartis Ag | IAP-inhibitorer |
| CA2569016C (en) | 2004-06-02 | 2012-11-27 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound |
| ES2438017T3 (es) * | 2004-07-30 | 2014-01-15 | Methylgene Inc. | Inhibidores de la señalización del receptor del VEGF y del receptor del HGF |
| JO2596B1 (en) * | 2004-11-30 | 2011-02-27 | نوفارتيس ايه جي | Compositions include epothelones and tyrosine protein kinase inhibitors and their pharmaceutical uses |
| CN101080227B (zh) * | 2004-12-15 | 2011-08-31 | 诺瓦提斯公司 | 用于治疗癌症的治疗剂的组合 |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| US20080219977A1 (en) * | 2005-07-27 | 2008-09-11 | Isaiah Josh Fidler | Combinations Comprising Gemcitabine and Tyrosine Kinase Inhibitors for the Treatment of Pancreatic Cancer |
| US20080227980A1 (en) * | 2005-08-05 | 2008-09-18 | Novartis Ag | Preparation of a 7H-Pyrrolo [2,3-D] Pyrimidine Derivative |
| NO20220050A1 (no) | 2005-11-21 | 2008-08-12 | Novartis Ag | Neuroendokrin tumorbehandling |
| CA2636954A1 (en) * | 2006-01-23 | 2007-07-26 | Novartis Ag | Solid forms of a pyrrolopyrimidine derivative and their use as anti-tumor agents |
| GB0605120D0 (en) | 2006-03-14 | 2006-04-26 | Novartis Ag | Organic Compounds |
| US20090098137A1 (en) | 2006-04-05 | 2009-04-16 | Novartis Ag | Combinations of therapeutic agents for treating cancer |
| CA2644143C (en) | 2006-04-05 | 2013-10-01 | Novartis Ag | Combinations comprising bcr-abl/c-kit/pdgf-r tk inhibitors for treating cancer |
| KR20080108516A (ko) * | 2006-04-05 | 2008-12-15 | 노파르티스 아게 | 암을 치료하기 위한 치료제의 조합물 |
| NZ572299A (en) | 2006-05-09 | 2010-07-30 | Novartis Ag | Combination comprising a substituted 3,5-diphenyl-1,2,4-triazole and a platinum compound and use thereof |
| WO2008037477A1 (en) | 2006-09-29 | 2008-04-03 | Novartis Ag | Pyrazolopyrimidines as p13k lipid kinase inhibitors |
| WO2008058126A2 (en) * | 2006-11-06 | 2008-05-15 | Supergen, Inc. | Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors |
| US20100069458A1 (en) | 2007-02-15 | 2010-03-18 | Peter Wisdom Atadja | Combination of lbh589 with other therapeutic agents for treating cancer |
| ES2424977T3 (es) * | 2007-08-08 | 2013-10-10 | Glaxosmithkline Intellectual Property Development Limited | Derivados de 2-[(2-{fenilamino}-1H-pirrolo[2,3-D]pirimidin-4-il)amino]benzamida como inhibidores de IGF-1R para el tratamiento del cáncer |
| AU2009228765B2 (en) | 2008-03-24 | 2012-05-31 | Novartis Ag | Arylsulfonamide-based matrix metalloprotease inhibitors |
| GEP20125708B (en) | 2008-03-26 | 2012-12-10 | Novartis Ag | Hydroxamate-based inhibitors of deacetylases b |
| KR101335843B1 (ko) | 2008-08-20 | 2013-12-02 | 조에티스 엘엘씨 | 피롤로[2,3-ｄ]피리미딘 화합물 |
| WO2010083617A1 (en) | 2009-01-21 | 2010-07-29 | Oncalis Ag | Pyrazolopyrimidines as protein kinase inhibitors |
| PL2391366T3 (pl) | 2009-01-29 | 2013-04-30 | Novartis Ag | Podstawione benzimidazole do leczenia gwiaździaków |
| WO2010099139A2 (en) | 2009-02-25 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Combination anti-cancer therapy |
| WO2010099363A1 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| WO2010099364A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| WO2010149755A1 (en) | 2009-06-26 | 2010-12-29 | Novartis Ag | 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17 |
| IN2012DN01251A (es) * | 2009-07-28 | 2015-05-15 | Ube Industries | |
| EA201200260A1 (ru) | 2009-08-12 | 2012-09-28 | Новартис Аг | Гетероциклические гидразоны и их применение для лечения рака и воспаления |
| NZ598220A (en) | 2009-08-17 | 2014-02-28 | Intellikine Llc | Heterocyclic compounds and uses thereof |
| CA2771432A1 (en) | 2009-08-20 | 2011-02-24 | Novartis Ag | Heterocyclic oxime compounds |
| IN2012DN01693A (es) | 2009-08-26 | 2015-06-05 | Novartis Ag | |
| AU2010317167B2 (en) | 2009-11-04 | 2012-11-29 | Novartis Ag | Heterocyclic sulfonamide derivatives useful as MEK inhibitors |
| CN102781237A (zh) | 2009-11-23 | 2012-11-14 | 天蓝制药公司 | 用于传递治疗剂的基于环糊精的聚合物 |
| EA201200823A1 (ru) | 2009-12-08 | 2013-02-28 | Новартис Аг | Гетероциклические производные сульфонамидов |
| US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
| CU24130B1 (es) | 2009-12-22 | 2015-09-29 | Novartis Ag | Isoquinolinonas y quinazolinonas sustituidas |
| US20110178287A1 (en) | 2010-01-19 | 2011-07-21 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutic delivery |
| UA112517C2 (uk) | 2010-07-06 | 2016-09-26 | Новартіс Аг | Тетрагідропіридопіримідинові похідні |
| MX2013002084A (es) | 2010-08-31 | 2013-05-09 | Genentech Inc | Biomarcadores y metodos de tratamiento. |
| JP2013537210A (ja) | 2010-09-16 | 2013-09-30 | ノバルティス アーゲー | １７α−ヒドロキシラーゼ／Ｃ１７，２０−リアーゼ阻害剤 |
| WO2012085815A1 (en) | 2010-12-21 | 2012-06-28 | Novartis Ag | Bi-heteroaryl compounds as vps34 inhibitors |
| EP2673277A1 (en) | 2011-02-10 | 2013-12-18 | Novartis AG | [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase |
| WO2012116237A2 (en) | 2011-02-23 | 2012-08-30 | Intellikine, Llc | Heterocyclic compounds and uses thereof |
| WO2012149014A1 (en) | 2011-04-25 | 2012-11-01 | OSI Pharmaceuticals, LLC | Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment |
| US9029399B2 (en) | 2011-04-28 | 2015-05-12 | Novartis Ag | 17α-hydroxylase/C17,20-lyase inhibitors |
| EA201391820A1 (ru) | 2011-06-09 | 2014-12-30 | Новартис Аг | Гетероциклические сульфонамидные производные |
| WO2012175520A1 (en) | 2011-06-20 | 2012-12-27 | Novartis Ag | Hydroxy substituted isoquinolinone derivatives |
| US8859586B2 (en) | 2011-06-20 | 2014-10-14 | Novartis Ag | Cyclohexyl isoquinolinone compounds |
| KR20140025530A (ko) | 2011-06-27 | 2014-03-04 | 노파르티스 아게 | 테트라히드로-피리도-피리미딘 유도체의 고체 형태 및 염 |
| ES2548414T3 (es) * | 2011-07-08 | 2015-10-16 | Novartis Ag | Novedosos derivados de pirrolo pirimidina |
| EP3795145A3 (en) | 2011-08-17 | 2021-06-09 | Dennis M. Brown | Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dibromodulcitol |
| CA2848809A1 (en) | 2011-09-15 | 2013-03-21 | Novartis Ag | 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyradines as c-met tyrosine kinase |
| WO2013080141A1 (en) | 2011-11-29 | 2013-06-06 | Novartis Ag | Pyrazolopyrrolidine compounds |
| JO3398B1 (ar) | 2011-12-22 | 2019-10-20 | Novartis Ag | مشتقات 2،3- ثانى هيدرو- بنزو[1,4] أوكسازين والمركبات المتعلقة بها كمثبطات كيناز فسفواينوسيتيد-3 (pi3k) لمعالجة على سبيل المثال التهاب المفاصل الروماتيدي |
| EP2794594A1 (en) | 2011-12-22 | 2014-10-29 | Novartis AG | Quinoline derivatives |
| WO2013096051A1 (en) | 2011-12-23 | 2013-06-27 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
| US20130178520A1 (en) | 2011-12-23 | 2013-07-11 | Duke University | Methods of treatment using arylcyclopropylamine compounds |
| BR112014015308A8 (pt) | 2011-12-23 | 2017-06-13 | Novartis Ag | compostos para inibição da interação de bcl2 com contrapartes de ligação |
| EP2794592A1 (en) | 2011-12-23 | 2014-10-29 | Novartis AG | Compounds for inhibiting the interaction of bcl2 with binding partners |
| US9126980B2 (en) | 2011-12-23 | 2015-09-08 | Novartis Ag | Compounds for inhibiting the interaction of BCL2 with binding partners |
| EP2794591A1 (en) | 2011-12-23 | 2014-10-29 | Novartis AG | Compounds for inhibiting the interaction of bcl2 with binding partners |
| UY34591A (es) | 2012-01-26 | 2013-09-02 | Novartis Ag | Compuestos de imidazopirrolidinona |
| AU2013243097A1 (en) | 2012-04-03 | 2014-10-09 | Novartis Ag | Combination products with tyrosine kinase inhibitors and their use |
| WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
| EP2855483B1 (en) | 2012-05-24 | 2017-10-25 | Novartis AG | Pyrrolopyrrolidinone compounds |
| EP2861256B1 (en) | 2012-06-15 | 2019-10-23 | The Brigham and Women's Hospital, Inc. | Compositions for treating cancer and methods for making the same |
| WO2014025395A1 (en) | 2012-08-06 | 2014-02-13 | Duke University | Compounds and methods for targeting hsp90 |
| US20150218173A1 (en) | 2012-09-26 | 2015-08-06 | Bayer Pharma Aktiengesellschaft | Substituted indazol-pyrrolopyrimidines useful in the treatment of hyperfoliferative disorders |
| WO2014048869A1 (en) | 2012-09-26 | 2014-04-03 | Bayer Pharma Aktiengesellschaft | Substituted indazol-pyrrolopyrimidines useful in the treatment of hyperproliferative diseases |
| CN102936251A (zh) * | 2012-11-05 | 2013-02-20 | 上海毕得医药科技有限公司 | 一种吡咯并[2,3-d]嘧啶衍生物的制备方法 |
| TW201422625A (zh) | 2012-11-26 | 2014-06-16 | Novartis Ag | 二氫－吡啶并－□衍生物之固體形式 |
| US9556180B2 (en) | 2013-01-22 | 2017-01-31 | Novartis Ag | Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction |
| WO2014115077A1 (en) | 2013-01-22 | 2014-07-31 | Novartis Ag | Substituted purinone compounds |
| WO2014128612A1 (en) | 2013-02-20 | 2014-08-28 | Novartis Ag | Quinazolin-4-one derivatives |
| JP2016509045A (ja) | 2013-02-22 | 2016-03-24 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | がんを治療し、薬剤耐性を防止する方法 |
| MX2015011428A (es) | 2013-03-06 | 2016-02-03 | Genentech Inc | Metodos para tratar y prevenir la resistencia a los farmacos para el cancer. |
| JP2016516046A (ja) | 2013-03-14 | 2016-06-02 | ジェネンテック， インコーポレイテッド | がんの治療方法及びがん薬物耐性を阻止する方法 |
| EP2968340A4 (en) | 2013-03-15 | 2016-08-10 | Intellikine Llc | COMBINING KINASE INHIBITORS AND USES THEREOF |
| CA2905123A1 (en) | 2013-03-15 | 2014-09-18 | Genentech, Inc. | Methods of treating cancer and preventing cancer drug resistance |
| WO2014155268A2 (en) | 2013-03-25 | 2014-10-02 | Novartis Ag | Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity |
| US20150018376A1 (en) | 2013-05-17 | 2015-01-15 | Novartis Ag | Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof |
| GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| DK4374873T3 (da) | 2013-07-12 | 2025-11-03 | Astellas Us Llc | Middel til brug ved behandling eller forebyggelse af oftalmologiske tilstande |
| UY35675A (es) | 2013-07-24 | 2015-02-27 | Novartis Ag | Derivados sustituidos de quinazolin-4-ona |
| WO2015022664A1 (en) | 2013-08-14 | 2015-02-19 | Novartis Ag | Compounds and compositions as inhibitors of mek |
| US9227969B2 (en) | 2013-08-14 | 2016-01-05 | Novartis Ag | Compounds and compositions as inhibitors of MEK |
| WO2015022663A1 (en) | 2013-08-14 | 2015-02-19 | Novartis Ag | Compounds and compositions as inhibitors of mek |
| KR20160060100A (ko) | 2013-09-22 | 2016-05-27 | 칼리토르 사이언시즈, 엘엘씨 | 치환된 아미노피리미딘 화합물 및 이용 방법 |
| TW201605450A (zh) | 2013-12-03 | 2016-02-16 | 諾華公司 | Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途 |
| RU2016141385A (ru) | 2014-03-24 | 2018-04-28 | Дженентек, Инк. | Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf |
| US10000469B2 (en) | 2014-03-25 | 2018-06-19 | Duke University | Heat shock protein 70 (hsp-70) receptor ligands |
| WO2015145388A2 (en) | 2014-03-27 | 2015-10-01 | Novartis Ag | Methods of treating colorectal cancers harboring upstream wnt pathway mutations |
| WO2015148867A1 (en) | 2014-03-28 | 2015-10-01 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
| BR112016022499A2 (pt) | 2014-04-03 | 2017-08-15 | Invictus Oncology Pvt Ltd | Produtos terapêuticos combinatórios supramoleculares |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| WO2016011658A1 (en) | 2014-07-25 | 2016-01-28 | Novartis Ag | Combination therapy |
| CN108064274A (zh) | 2014-07-30 | 2018-05-22 | 耶达研究及发展有限公司 | 用于培养多能干细胞的培养基 |
| CA2954862A1 (en) | 2014-07-31 | 2016-02-04 | Novartis Ag | Combination therapy |
| JP2018527362A (ja) | 2015-09-11 | 2018-09-20 | サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． | 置換されたヘテロアリール化合物および使用方法 |
| WO2017184775A1 (en) * | 2016-04-19 | 2017-10-26 | The Regents Of The University Of California | Erbb inhibitors and uses thereof |
| US11261187B2 (en) | 2016-04-22 | 2022-03-01 | Duke University | Compounds and methods for targeting HSP90 |
| US10927083B2 (en) | 2016-09-29 | 2021-02-23 | Duke University | Substituted benzimidazoles as inhibitors of transforming growth factor-β kinase |
| US10207998B2 (en) | 2016-09-29 | 2019-02-19 | Duke University | Substituted benzimidazole and substituted benzothiazole inhibitors of transforming growth factor-β kinase and methods of use thereof |
| JP2020505327A (ja) | 2016-12-23 | 2020-02-20 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | Ｅｇｆｒタンパク質分解標的化キメラ分子およびその関連する使用方法 |
| US10806737B2 (en) | 2016-12-23 | 2020-10-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides |
| WO2019099311A1 (en) | 2017-11-19 | 2019-05-23 | Sunshine Lake Pharma Co., Ltd. | Substituted heteroaryl compounds and methods of use |
| US11602534B2 (en) | 2017-12-21 | 2023-03-14 | Hefei Institutes Of Physical Science, Chinese Academy Of Sciences | Pyrimidine derivative kinase inhibitors |
| KR102737185B1 (ko) | 2018-01-20 | 2024-12-05 | 선샤인 레이크 파르마 컴퍼니 리미티드 | 치환된 아미노피리미딘 화합물 및 이의 사용 방법 |
| US12220423B2 (en) | 2018-07-24 | 2025-02-11 | Hygia Pharmaceuticals, Llc | Compounds, derivatives, and analogs for cancer |
| WO2020132384A1 (en) | 2018-12-21 | 2020-06-25 | Celgene Corporation | Thienopyridine inhibitors of ripk2 |
| EP3914698B1 (en) | 2019-01-23 | 2024-12-11 | Yeda Research and Development Co. Ltd | Culture media for pluripotent stem cells |
| NL2022471B1 (en) | 2019-01-29 | 2020-08-18 | Vationpharma B V | Solid state forms of oclacitinib |
| WO2020231990A1 (en) | 2019-05-13 | 2020-11-19 | Relay Therapeutics, Inc. | Fgfr inhibitors and methods of use thereof |
| WO2021185844A1 (en) | 2020-03-16 | 2021-09-23 | Pvac Medical Technologies Ltd | Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof |
| WO2021233534A1 (en) | 2020-05-20 | 2021-11-25 | Pvac Medical Technologies Ltd | Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof |
| CN115768890A (zh) | 2020-04-15 | 2023-03-07 | 加州理工学院 | 通过分子和物理启动对t细胞免疫疗法的热控制 |
| EP4192509A1 (en) | 2020-08-05 | 2023-06-14 | Ellipses Pharma Ltd | Treatment of cancer using a cyclodextrin-containing polymer-topoisomerase inhibitor conjugate and a parp inhibitor |
| US11814388B1 (en) | 2020-08-28 | 2023-11-14 | Ferris State University | Substituted pyrrolo[2,3-d]pyrimidines and pyrazolo[3,4-d]pyrimidines as inhibitors for multi-resistant cancers |
| WO2022047259A1 (en) | 2020-08-28 | 2022-03-03 | California Institute Of Technology | Synthetic mammalian signaling circuits for robust cell population control |
| GB2617409B (en) | 2022-04-27 | 2024-06-26 | Cancertain Ltd | Method for predicting responsiveness to therapy |
| CN119816589A (zh) | 2022-08-02 | 2025-04-11 | 国立大学法人北海道大学 | 使用细胞器复合体改善细胞疗法的方法 |
| WO2024091370A1 (en) * | 2022-10-26 | 2024-05-02 | Acerand Therapeutics (Usa) Limited | 5,6-fused bicyclic heteroaromatic compounds |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5877178A (en) * | 1991-04-08 | 1999-03-02 | Duquesne University Of The Holy Ghost | Pyrimidine derivatives and methods of making and using these derivatives |
| US5958930A (en) * | 1991-04-08 | 1999-09-28 | Duquesne University Of The Holy Ghost | Pyrrolo pyrimidine and furo pyrimidine derivatives |
| DE59500788D1 (de) | 1994-05-03 | 1997-11-20 | Ciba Geigy Ag | Pyrrolopyrimidinderivate mit antiproliferativer Wirkung |
| TW530047B (en) | 1994-06-08 | 2003-05-01 | Pfizer | Corticotropin releasing factor antagonists |
| SI9620103A (sl) * | 1995-07-06 | 1998-10-31 | Novartis Ag | Pirolopirimidini in postopki za njihovo pripravo |
| JPH09218320A (ja) * | 1996-02-14 | 1997-08-19 | Fujitsu Ltd | 光海底中継器 |
| GB9604361D0 (en) | 1996-02-29 | 1996-05-01 | Pharmacia Spa | 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors |
| WO1997047601A1 (en) | 1996-06-11 | 1997-12-18 | Yoshitomi Pharmaceutical Industries, Ltd. | Fused heterocyclic compounds and medicinal uses thereof |
| WO1998006703A1 (en) | 1996-08-14 | 1998-02-19 | Warner-Lambert Company | 2-phenyl benzimidazole derivatives as mcp-1 antagonists |
| WO1998007726A1 (en) * | 1996-08-23 | 1998-02-26 | Novartis Ag | Substituted pyrrolopyrimidines and processes for their preparation |
| WO1998043973A1 (de) | 1997-03-27 | 1998-10-08 | Novartis Ag | Zwischenprodukte und verfahren zur herstellung von pyrimidinderivaten |
| PA8474101A1 (es) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
| SK286640B6 (sk) | 1998-06-19 | 2009-03-05 | Pfizer Products Inc. | Pyrol [2,3-d] pyrimidínová zlúčenina, jej použitie na výrobu liečiva, farmaceutická kompozícia s jej obsahom, použitie jej kombinácie s ďalšími činidlami a súpravy s jej obsahom na výrobu liečiva |
| EP1040831A3 (en) | 1999-04-02 | 2003-05-02 | Pfizer Products Inc. | Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death |
| PL354784A1 (en) | 1999-09-30 | 2004-02-23 | Neurogen Corporation | Certain alkylene diamine-substituted heterocycles |
| ITMI992711A1 (it) | 1999-12-27 | 2001-06-27 | Novartis Ag | Composti organici |
| IL150594A0 (en) | 2000-01-07 | 2003-02-12 | Ustav Ex Botan Adademie Ved Ce | Purine derivatives, process for their preparation and use |
| HUP0204272A3 (en) | 2000-01-18 | 2005-03-29 | Pfizer Prod Inc | Corticotropin releasing factor antagonists, pharmaceutical compositions containing them and their use |
| AU9598601A (en) | 2000-10-20 | 2002-04-29 | Eisai Co Ltd | Nitrogenous aromatic ring compounds |
-
2001
- 2001-08-07 GB GBGB0119249.1A patent/GB0119249D0/en not_active Ceased
-
2002
- 2002-08-05 AR ARP020102968A patent/AR036213A1/es active IP Right Grant
- 2002-08-05 PE PE2002000710A patent/PE20030349A1/es not_active Application Discontinuation
- 2002-08-05 TW TW091117568A patent/TWI324159B/zh not_active IP Right Cessation
- 2002-08-06 PT PT02758437T patent/PT1416935E/pt unknown
- 2002-08-06 CN CN2009101378774A patent/CN101560214B/zh not_active Expired - Fee Related
- 2002-08-06 ES ES02758437T patent/ES2302830T3/es not_active Expired - Lifetime
- 2002-08-06 JP JP2003518550A patent/JP4147184B2/ja not_active Expired - Fee Related
- 2002-08-06 DK DK02758437T patent/DK1416935T3/da active
- 2002-08-06 AT AT02758437T patent/ATE388713T1/de active
- 2002-08-06 CA CA2453881A patent/CA2453881C/en not_active Expired - Fee Related
- 2002-08-06 SI SI200230695T patent/SI1416935T1/sl unknown
- 2002-08-06 BR BR0211801-7A patent/BR0211801A/pt active Search and Examination
- 2002-08-06 DE DE60225563T patent/DE60225563T2/de not_active Expired - Lifetime
- 2002-08-06 NZ NZ530824A patent/NZ530824A/en not_active IP Right Cessation
- 2002-08-06 US US10/485,747 patent/US7244729B2/en not_active Expired - Fee Related
- 2002-08-06 HU HU0401083A patent/HUP0401083A3/hu unknown
- 2002-08-06 PL PL02365783A patent/PL365783A1/xx unknown
- 2002-08-06 SG SG200600778-5A patent/SG156521A1/en unknown
- 2002-08-06 MX MXPA04001191A patent/MXPA04001191A/es active IP Right Grant
- 2002-08-06 KR KR1020047001944A patent/KR100597505B1/ko not_active Expired - Fee Related
- 2002-08-06 CN CNA028153510A patent/CN1538847A/zh active Pending
- 2002-08-06 AU AU2002324029A patent/AU2002324029B2/en not_active Ceased
- 2002-08-06 WO PCT/EP2002/008780 patent/WO2003013541A1/en not_active Ceased
- 2002-08-06 MY MYPI20022923A patent/MY140398A/en unknown
- 2002-08-06 RU RU2004106783/04A patent/RU2318826C2/ru not_active IP Right Cessation
- 2002-08-06 EP EP02758437A patent/EP1416935B8/en not_active Expired - Lifetime
- 2002-08-06 IL IL15983202A patent/IL159832A0/xx unknown
-
2003
- 2003-01-21 EC EC2003004444A patent/ECSP034444A/es unknown
-
2004
- 2004-01-12 IL IL159832A patent/IL159832A/en not_active IP Right Cessation
- 2004-01-14 ZA ZA200400271A patent/ZA200400271B/en unknown
- 2004-02-05 NO NO20040540A patent/NO328791B1/no not_active IP Right Cessation
-
2007
- 2007-03-14 US US11/686,023 patent/US7390805B2/en not_active Expired - Fee Related
-
2008
- 2008-06-10 CY CY20081100612T patent/CY1108129T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR036213A1 (es) | Derivados de 6-fenil-pirrolo[2,3-d]pirimidina, un proceso para su preparacion, composicion farmaceutica y el uso de dichos derivados para la preparacion de composiciones farmaceuticas | |
| ECSP045073A (es) | Nuevos derivados de piperazina | |
| ES2322602T3 (es) | Compuestos heterotetraciclicos condensados y su uso como inhibidor de polimerasa del vhc. | |
| AR083052A1 (es) | Inhibidores de las proteasas de serina del vhc derivados de prolinas macrociclicas | |
| CO5590957A2 (es) | Amino-1,3,5-triazinas sustituidas en n con radicales biciclicos quirales, procedimiento para su preparacion, composiciones de las mismas y su uso como herbicidas y reguladores del crecimiento de las plantas | |
| IL159087A0 (en) | Bridged bicyclic compounds and pharmaceutical compositions containing the same | |
| AR045134A1 (es) | Compuesto de 1h - imidazo [4,5-c] piridin-ilo, composicion farmaceutica que lo comprende, proceso para prepararla, su uso para preparar dicha composicion farmaceutica, combinacion farmaceutica, uso de la combinacion farmaceutica para la preparacion de un medicamento, procedimientos para preparar dic | |
| AR059339A1 (es) | Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene | |
| HUP0301351A2 (hu) | Helyettesített dipeptidszármazékok eljárás az előállításukra alkalmazásuk növekedési hormon szekretagóg hatóanyagokként, és ezeket tartalmazó gyógyszerkészítmények | |
| ATE336991T1 (de) | Bis(thio-hydrazid amid) verbindungen zur behandlung von mehrfach resistenten krebs | |
| PE20080144A1 (es) | Compuestos de tetrahidropiridotienopirimidina con actividad antiproliferativa | |
| EP2368900A3 (en) | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease | |
| AR067475A1 (es) | Antagonistas no basico s del receptor de la hormona concentradora de melanina 1 | |
| AR046297A1 (es) | Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo | |
| TW200510391A (en) | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | |
| CA2428271A1 (en) | Cyanopyrrolidine derivatives as inhibitors of dpp-iv | |
| AR035617A1 (es) | Compuestos derivados de fenetanolamina, combinaciones y formulaciones farmaceuticas de los mismos, proceso para su preparacion, su uso en la preparacion de medicamentos para el tratamiento o profilaxis de una condicion clinica para la cual se indica un agonista beta2 adreno-receptor e intermediarios | |
| AR034858A1 (es) | Compuestos elevadores de abca-1,composicion farmaceutica y el uso de los mismos para la manufactura de un medicamento | |
| BRPI0511768A (pt) | composto, pró-droga, métodos para a produção de um composto, e para a profilaxia ou tratamento de cáncer em um mamìfero, agente farmacêutico, e, uso de um composto | |
| UY27368A1 (es) | Nuevos compuestos | |
| RU2009125578A (ru) | Новые замещенные диазаспиропиридиноновые производные для применения в лечении мсн-1-опосредованных заболеваний | |
| AR029151A1 (es) | Una sal cuaternaria de piperidina, su uso, un proceso para su preparacion, y una composicion farmaceutica que la contiene | |
| AR064253A1 (es) | Compuestos de biciclocarboxiamida sustituidos composiciones farmaceuticas y una combinacion que los incluye y su uso en fabaricacion de un medicamento para el tratamiento de enfermedades mediadas por la actividad del receptor vr1 | |
| BRPI0310032B8 (pt) | derivados de benzoxazina, seus usos e seus processos de produção, e composição farmacêutica | |
| UY27593A1 (es) | Nuevos compuestos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FG | Grant, registration |